The first factor is the robust health of the overall addressable market for cannabinoid products. The “total cannabinoid market” — state-licensed plus hemp-derived plus FDA-approved pharmaceuticals — reached $57 billion in 2025. It grew at a 20% compound annual rate from 2020 through 2025, with the hemp-derived channel taking over for the state-licensed market as the chief engine of growth.

The three channels taken together are almost twice the size of, and growing twice as fast as, the licensed-cannabis pipeline alone. Licensed cannabis retailers — public multi-state operators (MSOs), private regional chains, and the independents that hold most of the market — are well positioned to roll up that broader demand, given the latest regulatory tremors in Washington and the states.

The second factor is the imminence of substantial changes in that total cannabinoid market. The November 12, 2026 federal hemp ban is six months away from taking effect, with no legislative fix in sight. The April 23, 2026 Schedule III rescheduling of medical marijuana enhances dispensary free cash flow and competitive positioning. Together, those two events should redirect at least some hemp-derived demand into the licensed channel and retire the threat of pharmaceutical competition — both gifts delivered by regulators, more or less by accident, to licensed retailers.

Three channels, $57 billion

Wall Street has ignored that, in total, the three legal channels of the total cannabinoid market are one of the fastest growing consumer product categories of all time — running at a 20% compound annual growth rate (CAGR) 2020-2025, and an eye-watering 29% CAGR over the full 2014-2025 stretch since Colorado legalized adult use. In recent years only GLP-1 drugs (Ozempic et al.) have come close to generating that kind of demand in a hurry, growing at 41% CAGR over eight years to $47 billion — but with insurance paying for most of it at pharmacies.

Demand for cannabinoids flows through three legal channels, separated mainly by government’s incoherent approach to regulating them. But the products are essentially the same, and consumers get the connection. Before there was pharmaceutical Epidiolex, hundreds of “medical refugee” families moved to Colorado for the high-CBD Charlotte’s Web strain, used by parents of kids with Dravet and Lennox-Gastaut syndromes.

State-licensed cannabis gets all the ink — medical and adult-use retail in the 40 states with active programs, dominated by private operators alongside public MSOs like Curaleaf, Green Thumb, Cresco, Verano, and Trulieve. Hemp-derived cannabinoid products — CBD plus the intoxicating hemp compounds that emerged after the 2018 Farm Bill — sit in a state-by-state framework that makes them legal in 32 states. It’s dominated by privately held companies, with a handful of public ones like Charlotte’s Web. FDA-approved pharmaceuticals, mainly Epidiolex, are the third channel, with Jazz Pharmaceuticals the main public stock option.

In 2025, the total cannabinoid market broke down into $30.9 billion in the licensed cannabis channel (BDSA’s April 2026 forecast), $24.6 billion in hemp-derived spending in states that legally permit it (Adams Research estimates, drawing on Whitney Economics, Brightfield Group, USDA and state data sets), and $1.7 billion for U.S. pharmaceutical cannabinoid consumer spending (our estimate based on Jazz Pharmaceuticals filings and IQVIA data).

The matched-definition framing matters. The hemp numbers (see graph) apply a legal-share haircut — counting only the roughly 77% of consumer demand in states with affirmative regulatory frameworks for hemp-derived cannabinoid products — to put it on the same footing as BDSA’s licensed-cannabis figure, which excludes illicit-market sales.

DC kicks off a game of “capture the flag”

Two structure-shaking events in recent months should redirect more cannabinoid demand toward the licensed channel. The hemp ban passed in November 2025’s budget reconciliation bill will close the 2018 Farm Bill loophole that let intoxicating cannabinoid products proliferate, effective November 12, 2026 — now six months away. The April 2026 rescheduling of medical marijuana removed federal regulatory friction from state-licensed medical cannabis programs while leaving the hemp ban untouched.

Assuming the hemp ban takes effect in November, hemp-derived demand will redirect to licensed cannabis at a capture rate that depends on state enforcement and the availability of licensed alternatives. If even a quarter of the hemp-derived market shifts, the channel becomes dominant again (see “Did the Feds Just Double the Growth Rate of Legal Cannabis?”). Updated with BDSA’s April 2026 updated forecast, the math is sharper still: the US licensed market projected at $37 billion by 2030 lifts to roughly $47 billion at 25 percent capture.

Curaleaf chairman Boris Jordan, on the company’s Q4 2025 earnings call in February, suggested the capture figure could be 50 percent — citing observed revenue gains in Massachusetts after that state’s hemp tightening. At Jordan’s 50 percent, the 2030 incremental nearly doubles to $19.7 billion and the licensed-channel’s CAGR 2025-2030 clears 12 percent.

Texas will be the bellwether state in this reordering of the total cannabinoid market. Last year’s HB 46 brought 31.9 million people into a real medical market and quintupled the licensed dispensary count from three to fifteen, all of whom can now operate statewide. The hemp regulatory situation in Texas — Governor Abbott’s veto of a sweeping ban, an executive order regulating without prohibiting, a live state-court fight over those rules — determines how much the medical expansion captures redirected hemp demand. With political cover for medical cannabis now beaming out of Washington, North Carolina, Wisconsin, Tennessee, Indiana, Kansas, and Idaho are plausible follow-ons.

What November 12 will test

With the hemp ban due to take effect November 12, fix efforts are stalled for now. The Hemp Planting Predictability Act, the U.S. Hemp Roundtable’s principal legislative push, would delay the deadline two years; the Wyden–Merkley Cannabinoid Safety and Regulation Act would replace the ban with a regulatory framework. Neither has cleared a committee hearing, so it seems likely that the licensed channel will get a window in which to recapture some of the growth it has yielded to hemp in recent years.

Most public cannabis operators positioned themselves defensively for the hemp boom. Curaleaf dabbled a bit, but chairman Boris Jordan called hemp a non-needle-mover at MJBizCon in December and wound the company’s hemp operations down through Q1. Cresco, Verano and Trulieve never materially entered hemp and lobbied for the ban Curaleaf is now complying with. Green Thumb, through its complex deal to license its brands to Agrify (now RYTHM, traded in the US on Nasdaq as RYM), is the most flexibly positioned MSO across both the state-licensed and federally-legal hemp channels. Post-ban, it has continued to push those brands into hemp-THC beverages in deals with Chicago’s United Center and Navy Pier.

The total cannabinoid market is the right lens for valuing what comes next. The case for licensed cannabis companies — emerging from the turmoil ahead in strong shape — rests on three structural facts: an addressable market roughly twice the dispensary line and growing twice as fast; federal action delivering more of that market to licensed retailers; and a fragmented field — where the public MSOs are a minority share of the licensed channel and a smaller share still of the total cannabinoid market.

All of that leads to the natural next stage of cannabinoid market development, and it leaves room for disciplined consolidators, public, private, or new entrant, to roll up the redirect. That’s the structural change investors should be valuing and executives should be planning around — not the shrinking dispensary growth rates people keep mistaking for the whole story.